Rozlytrek

Quick orientation

Rozlytrek (entrectinib) is an oral ROS1 and tropomyosin receptor kinase (TRK) inhibitor developed by Genentech, a member of the Roche Group. The US Food and Drug Administration approved Rozlytrek in August 2019 for adult patients with metastatic ROS1-positive non-small cell lung cancer, and for adult and paediatric patients 12 years and older with solid tumours that harbour an NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. The drug is given as a 600 mg oral capsule once daily for adults, with weight-based dosing for paediatric patients. Selection requires validated ROS1 or NTRK gene fusion testing.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

How Reserve Meds coordinates Rozlytrek

1. Patient or treating physician submits an intake at the patient portal.
2. Reserve Meds clinical team verifies appropriateness for the patient and destination country.
3. Treating physician issues prescription and clinical justification.
4. Country-specific named-patient documentation is prepared.
5. Rozlytrek is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
6. Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.

Access by country

Reserve Meds publishes a detailed country access guide for Rozlytrek in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.

Start a request for Rozlytrek

Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.

Start your case Or message us on WhatsApp